AtriCure (ATRC) Cash & Equivalents (2010 - 2026)

AtriCure (ATRC) has reported Cash & Equivalents for 17 consecutive years, with $167.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 42.44% year-over-year to $167.8 million; the TTM figure through Jun 2026 stood at $167.8 million (up 42.44% YoY), while the FY2025 annual figure was $167.4 million, up 36.43% from the prior year.
• Cash & Equivalents advanced to $167.8 million in Q2 2026 per ATRC's latest filing, from $146.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $167.8 million in Q2 2026 and bottomed at $28.1 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $98.3 million across 5 years, with a median of $92.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 67.04% — and 2023, when it jumped 174.83%.
• AtriCure's Cash & Equivalents stood at $58.1 million in 2022, then soared by 45.11% to $84.3 million in 2023, then soared by 45.56% to $122.7 million in 2024, then soared by 36.43% to $167.4 million in 2025, then climbed by 0.21% to $167.8 million in 2026.
• Business Quant data shows ATRC's Cash & Equivalents at $167.8 million in Q2 2026, $146.2 million in Q1 2026, and $167.4 million in Q4 2025.